Hikma Pharmaceuticals PLC (HIK)

Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

1,952.00p

Buy

1,954.00p

arrow-down-8.00p (-0.41%)

Prices updated at 27 Nov 2024, 16:35 GMT
| Prices minimum 15 mins delay
|
Prices in GBX
Hikma Pharmaceuticals PLC develops, manufactures and markets a broad range of branded and non-branded generic pharmaceutical products across the US, the MENA region, and Europe.
FTSE All-Share
arrow-up0.19%
LSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.

Most recent dividend payment

0.320
Cash Dividend
15 Aug 2024
08 Aug 2024
16 Aug 2024
20 Sep 2024

Total dividend yield

Dividend history and forecast data table

YearDividend per shareDividend growth (%)
20240.7900-
20230.49410.17
20220.42000.02
20210.37700.13
20200.36220.07
20190.34000.25
20180.25400.05
20170.30500.04
20160.22920.24
20150.20450.28

Total dividend yield data table

Year
chevron-l-regular
chevron-r-regular
Dividend yield (%)Buyback yield (%)
20242.51-
20232.76-
20222.717.28
20211.70-
20201.44-
20191.71-
20181.48-
20172.24-
20161.21-
20150.72-

Dividend per share

% of earnings paid to shareholders

Dividend per share data table

YearDividend per share
20240.7900
20230.4941
20220.4200
20210.3770
20200.3622
20190.3400
20180.2540
20170.3050
20160.2292
20150.2045

% of earnings paid to shareholders data table

YearPayout ratio (%)
202472.75
202382.79
202234.76
202124.89
202022.27
201925.75
2018-
201747.60
201637.95
201517.80
Latest Financial Report as of 26 Nov 2024
Dividend amount and dividend per share are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2024 Morningstar. All rights reserved.